{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:36:11Z","timestamp":1794407771692,"version":"4.9.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Aging","award":["K99AG071837"],"award-info":[{"award-number":["K99AG071837"]}]},{"name":"National Institute of Aging","award":["K99AG075238"],"award-info":[{"award-number":["K99AG075238"]}]},{"name":"National Institute of Aging","award":["P30AG066515"],"award-info":[{"award-number":["P30AG066515"]}]},{"name":"National Institute of Aging","award":["K01AG051718"],"award-info":[{"award-number":["K01AG051718"]}]},{"name":"National Institute of Aging","award":["P01AG036694"],"award-info":[{"award-number":["P01AG036694"]}]},{"name":"National Institute of Aging","award":["P50AG005134"],"award-info":[{"award-number":["P50AG005134"]}]},{"name":"National Institute of Aging","award":["U24AG074855"],"award-info":[{"award-number":["U24AG074855"]}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS115114"],"award-info":[{"award-number":["R01NS115114"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["AARFD-21-849349"],"award-info":[{"award-number":["AARFD-21-849349"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["AARF-20-683984"],"award-info":[{"award-number":["AARF-20-683984"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>APOE<\/jats:italic>\n                      variants are strongly associated with abnormal amyloid aggregation and additional direct effects of\n                      <jats:italic>APOE<\/jats:italic>\n                      on tau aggregation are reported in animal and human cell models. The degree to which these effects are present in humans when individuals are clinically unimpaired (CU) but have abnormal amyloid (A\u03b2+) remains unclear.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed data from CU individuals in the Anti-Amyloid Treatment in Asymptomatic AD (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies. Amyloid PET data were available for 4486 participants (3163 A\u03b2-, 1323 A\u03b2+) and tau PET data were available for a subset of 447 participants (55 A\u03b2-, 392 A\u03b2+). Linear models examined\n                      <jats:italic>APOE<\/jats:italic>\n                      (number of e2 and e4 alleles) associations with global amyloid and regional tau burden in medial temporal lobe (entorhinal, amygdala) and early neocortical regions (inferior temporal, inferior parietal, precuneus). Consistency of\n                      <jats:italic>APOE<\/jats:italic>\n                      4 effects on regional tau were examined in 220 A\u03b2\u00a0+\u2009CU and mild cognitive impairment (MCI) participants from the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>APOE<\/jats:italic>\n                      2 and\n                      <jats:italic>APOE<\/jats:italic>\n                      4 were associated with lower and higher amyloid positivity rates, respectively. Among A\u03b2+\u2009CU, e2 and e4 were associated with reduced (\u221212 centiloids\u00a0per allele) and greater (+15 centiloids\u00a0per allele) continuous amyloid burden, respectively.\n                      <jats:italic>APOE<\/jats:italic>\n                      2 was associated with reduced regional tau in all regions (-0.05 to -0.09 SUVR per allele), whereas\n                      <jats:italic>APOE<\/jats:italic>\n                      4 was associated with greater regional tau (+0.02 to +0.07 SUVR per allele).\n                      <jats:italic>APOE<\/jats:italic>\n                      differences were confirmed by contrasting e3\/e3 with e2\/e3 and e3\/e4. Mediation analyses among A\u03b2+\u2009s showed that direct effects of e2 on regional tau were present in medial temporal lobe and early neocortical regions, beyond an indirect pathway mediated by continuous amyloid burden. For e4, direct effects on regional tau were only significant in medial temporal lobe. The magnitude of protective e2 effects on regional tau was consistent across brain regions, whereas detrimental e4 effects were greatest in medial temporal lobe.\n                      <jats:italic>APOE<\/jats:italic>\n                      4 patterns were confirmed in A\u03b2+\u2009ADNI participants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:italic>APOE<\/jats:italic>\n                      influences early regional tau PET burden, above and beyond effects related to cross-sectional amyloid PET burden. Therapeutic strategies targeting underlying mechanisms related to\n                      <jats:italic>APOE<\/jats:italic>\n                      may modify tau accumulation among A\u03b2+\u2009individuals.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13024-022-00590-4","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T20:02:22Z","timestamp":1672776142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["APOE effects on regional tau in preclinical Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9535-2137","authenticated-orcid":false,"given":"Christina B.","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Belloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S.","family":"Insel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Greicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa A.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Poston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Mormino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the A4 Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"590_CR1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng0694-180","volume":"7","author":"EH Corder","year":"1994","unstructured":"Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180\u20134.","journal-title":"Nat Genet"},{"key":"590_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261:921\u20133.","journal-title":"Science"},{"key":"590_CR3","doi-asserted-by":"publisher","first-page":"200.e13","DOI":"10.1016\/j.neurobiolaging.2016.02.024","volume":"41","author":"PG Ridge","year":"2016","unstructured":"Ridge PG, Hoyt KB, Boehme K, Mukherjee S, Crane PK, Haines JL, et al. Assessment of the genetic variance of late-onset Alzheimer\u2019s disease. Neurobiol Aging. 2016;41:200.e13\u201320.","journal-title":"Neurobiol Aging"},{"key":"590_CR4","doi-asserted-by":"publisher","first-page":"e1605","DOI":"10.1212\/WNL.0000000000005415","volume":"90","author":"T Ge","year":"2018","unstructured":"Ge T, Sabuncu MR, Smoller JW, Sperling RA, Mormino EC. Dissociable influences of APOE \u03b54 and polygenic risk of AD dementia on amyloid and cognition. Neurology. 2018;90:e1605\u201312.","journal-title":"Neurology"},{"key":"590_CR5","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2015.4669","volume":"313","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BNM, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313:1939\u201349.","journal-title":"JAMA"},{"key":"590_CR6","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1212\/WNL.0000000000004336","volume":"89","author":"YY Lim","year":"2017","unstructured":"Lim YY, Mormino EC. Alzheimer\u2019s Disease Neuroimaging Initiative. APOE genotype and early \u03b2-amyloid accumulation in older adults without dementia. Neurology. 2017;89:1028\u201334.","journal-title":"Neurology"},{"key":"590_CR7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3233\/JAD-181282","volume":"69","author":"JB Toledo","year":"2019","unstructured":"Toledo JB, Habes M, Sotiras A, Bjerke M, Fan Y, Weiner MW, et al. APOE effect on amyloid-\u03b2 PET spatial distribution, deposition rate, and cut-points. J Alzheimers Dis JAD. 2019;69:783\u201393.","journal-title":"J Alzheimers Dis JAD"},{"key":"590_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"C-C Liu","year":"2013","unstructured":"Liu C-C, Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106\u201318.","journal-title":"Nat Rev Neurol"},{"key":"590_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev-pathmechdis-030421-112756","volume":"17","author":"N Koutsodendris","year":"2022","unstructured":"Koutsodendris N, Nelson MR, Rao A, Huang Y. Apolipoprotein E and Alzheimer\u2019s disease: findings, hypotheses, and potential mechanisms. Annu Rev Pathol. 2022;17:73\u201399.","journal-title":"Annu Rev Pathol"},{"key":"590_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13024-022-00566-4","volume":"17","author":"R Fern\u00e1ndez-Calle","year":"2022","unstructured":"Fern\u00e1ndez-Calle R, Konings SC, Fronti\u00f1\u00e1n-Rubio J, Garc\u00eda-Revilla J, Camprub\u00ed-Ferrer L, Svensson M, et al. APOE in the Bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer\u2019s disease pathology and brain diseases. Mol Neurodegener. 2022;17:62.","journal-title":"Mol Neurodegener"},{"key":"590_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.neurobiolaging.2020.05.012","volume":"94","author":"BJ Lopresti","year":"2020","unstructured":"Lopresti BJ, Campbell EM, Yu Z, Anderson SJ, Cohen AD, Minhas DS, et al. Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories. Neurobiol Aging. 2020;94:111\u201320.","journal-title":"Neurobiol Aging"},{"key":"590_CR12","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","volume":"76","author":"BJ Hanseeuw","year":"2019","unstructured":"Hanseeuw BJ, Betensky RA, Jacobs HIL, Schultz AP, Sepulcre J, Becker JA, et al. Association of Amyloid and tau with Cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 2019;76:915\u201324.","journal-title":"JAMA Neurol"},{"key":"590_CR13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2021.1858","volume":"78","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 2021;78:961\u201371.","journal-title":"JAMA Neurol"},{"key":"590_CR14","doi-asserted-by":"crossref","unstructured":"Strikwerda-Brown C, Hobbs DA, Gonneaud J, St-Onge F, Binette AP, Ozlen H, et al. Association of elevated amyloid and tau positron emission tomography signal with near-term development of alzheimer disease symptoms in older adults without cognitive impairment. JAMA Neurol. 2022;79:975\u201385.","DOI":"10.1001\/jamaneurol.2022.2379"},{"key":"590_CR15","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1093\/brain\/awz268","volume":"142","author":"CR Jack","year":"2019","unstructured":"Jack CR, Wiste HJ, Botha H, Weigand SD, Therneau TM, Knopman DS, et al. The bivariate distribution of amyloid-\u03b2 and tau: relationship with established neurocognitive clinical syndromes. Brain J Neurol. 2019;142:3230\u201342.","journal-title":"Brain J Neurol"},{"key":"590_CR16","doi-asserted-by":"publisher","first-page":"e650","DOI":"10.1212\/WNL.0000000000011270","volume":"96","author":"R La Joie","year":"2021","unstructured":"La Joie R, Visani AV, Lesman-Segev OH, Baker SL, Edwards L, Iaccarino L, et al. Association of APOE4 and clinical variability in Alzheimer disease with the pattern of tau- and amyloid-PET. Neurology. 2021;96:e650\u201361.","journal-title":"Neurology"},{"key":"590_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jamaneurol.2018.4693","volume":"76","author":"RF Buckley","year":"2019","unstructured":"Buckley RF, Mormino EC, Rabin JS, Hohman TJ, Landau S, Hanseeuw BJ, et al. Sex differences in the Association of Global Amyloid and Regional tau Deposition Measured by positron emission tomography in clinically Normal older adults. JAMA Neurol. 2019;76:542\u201351.","journal-title":"JAMA Neurol"},{"key":"590_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/brain\/awz378","volume":"143","author":"TJ Betthauser","year":"2020","unstructured":"Betthauser TJ, Koscik RL, Jonaitis EM, Allison SL, Cody KA, Erickson CM, et al. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Brain J Neurol. 2020;143:320\u201335.","journal-title":"Brain J Neurol"},{"key":"590_CR19","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1212\/WNL.0000000000007728","volume":"93","author":"VJ Lowe","year":"2019","unstructured":"Lowe VJ, Bruinsma TJ, Wiste HJ, Min H-K, Weigand SD, Fang P, et al. Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology. 2019;93:e29\u201339.","journal-title":"Neurology"},{"key":"590_CR20","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","volume":"157","author":"A Maass","year":"2017","unstructured":"Maass A, Landau S, Baker SL, Horng A, Lockhart SN, La Joie R, et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer\u2019s disease. NeuroImage. 2017;157:448\u201363.","journal-title":"NeuroImage"},{"key":"590_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13195-018-0403-x","volume":"10","author":"N Mattsson","year":"2018","unstructured":"Mattsson N, Ossenkoppele R, Smith R, Strandberg O, Ohlsson T, J\u00f6gi J, et al. Greater tau load and reduced cortical thickness in APOE \u03b54-negative Alzheimer\u2019s disease: a cohort study. Alzheimers Res Ther. 2018;10:77.","journal-title":"Alzheimers Res Ther"},{"key":"590_CR22","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2019.4421","volume":"77","author":"J Therriault","year":"2020","unstructured":"Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Chamoun M, Savard M, et al. Association of Apolipoprotein E \u03b54 with medial temporal tau independent of amyloid-\u03b2. JAMA Neurol. 2020;77:470\u20139.","journal-title":"JAMA Neurol"},{"key":"590_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13195-020-00710-6","volume":"12","author":"MS Baek","year":"2020","unstructured":"Baek MS, Cho H, Lee HS, Lee JH, Ryu YH, Lyoo CH. Effect of APOE \u03b54 genotype on amyloid-\u03b2 and tau accumulation in Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12:140.","journal-title":"Alzheimers Res Ther"},{"key":"590_CR24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014;370:322\u201333.","journal-title":"N Engl J Med"},{"key":"590_CR25","first-page":"210","volume":"10","author":"VJ Lowe","year":"2018","unstructured":"Lowe VJ, Bruinsma TJ, Min H-K, Lundt ES, Fang P, Senjem ML, et al. Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. Alzheimers Dement Diagn Assess Dis Monit. 2018;10:210\u20136.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"590_CR26","doi-asserted-by":"publisher","first-page":"e1913909","DOI":"10.1001\/jamanetworkopen.2019.13909","volume":"2","author":"VK Ramanan","year":"2019","unstructured":"Ramanan VK, Castillo AM, Knopman DS, Graff-Radford J, Lowe VJ, Petersen RC, et al. Association of Apolipoprotein E \u025b4, educational level, and sex with tau deposition and tau-mediated metabolic dysfunction in older adults. JAMA Netw Open. 2019;2:e1913909.","journal-title":"JAMA Netw Open"},{"key":"590_CR27","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00259-020-05099-w","volume":"48","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Leuzy A, Cho H, Sudre CH, Strandberg O, Smith R, et al. The impact of demographic, clinical, genetic, and imaging variables on tau PET status. Eur J Nucl Med Mol Imaging. 2021;48:2245\u201358.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"590_CR28","doi-asserted-by":"crossref","unstructured":"Ghisays V, Goradia DD, Protas H, Bauer RJ, Devadas V, Tariot PN, et al. Brain imaging measurements of fibrillar amyloid-\u03b2 burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE \u03b54 allele. Alzheimers Dement. 2020;16:598-609.","DOI":"10.1016\/j.jalz.2019.08.195"},{"issue":"6","key":"590_CR29","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/jamaneurol.2022.0676","volume":"79","author":"CB Young","year":"2022","unstructured":"Young CB, Winer JR, Younes K, Cody KA, Betthauser TJ, Johnson SC, et al. Divergent cortical tau positron emission tomography patterns among patients with preclinical Alzheimer disease. JAMA Neurol. 2022;79(6):592\u2013603.","journal-title":"JAMA Neurol"},{"key":"590_CR30","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaneurol.2020.0387","volume":"77","author":"RA Sperling","year":"2020","unstructured":"Sperling RA, Donohue MC, Raman R, Sun C-K, Yaari R, Holdridge K, et al. Association of Factors with Elevated Amyloid Burden in clinically Normal older individuals. JAMA Neurol. 2020;77:735\u201345.","journal-title":"JAMA Neurol"},{"key":"590_CR31","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jalz.2018.02.009","volume":"14","author":"N Mattsson","year":"2018","unstructured":"Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, et al. Prevalence of the apolipoprotein E \u03b54 allele in amyloid \u03b2 positive subjects across the spectrum of Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc. 2018;14:913\u201324.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"590_CR32","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1007\/s00259-021-05192-8","volume":"48","author":"G Salvad\u00f3","year":"2021","unstructured":"Salvad\u00f3 G, Grothe MJ, Groot C, Moscoso A, Sch\u00f6ll M, Gispert JD, et al. Differential associations of APOE-\u03b52 and APOE-\u03b54 alleles with PET-measured amyloid-\u03b2 and tau deposition in older individuals without dementia. Eur J Nucl Med Mol Imaging. 2021;48:2212\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"590_CR33","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41467-019-14279-8","volume":"11","author":"EM Reiman","year":"2020","unstructured":"Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ, et al. Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11:667.","journal-title":"Nat Commun"},{"key":"590_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.neurobiolaging.2015.09.011","volume":"37","author":"JM Farfel","year":"2016","unstructured":"Farfel JM, Yu L, De Jager PL, Schneider JA, Bennett DA. Association of APOE with tau-tangle pathology with and without \u03b2-amyloid. Neurobiol Aging. 2016;37:19\u201325.","journal-title":"Neurobiol Aging"},{"key":"590_CR35","doi-asserted-by":"publisher","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","volume":"6","author":"RA Sperling","year":"2014","unstructured":"Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6:228fs13.","journal-title":"Sci Transl Med"},{"key":"590_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","volume":"13","author":"SK Royse","year":"2021","unstructured":"Royse SK, Minhas DS, Lopresti BJ, Murphy A, Ward T, Koeppe RA, et al. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimers Res Ther. 2021;13:99.","journal-title":"Alzheimers Res Ther"},{"key":"590_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13024-020-00413-4","volume":"15","author":"Z Li","year":"2020","unstructured":"Li Z, Shue F, Zhao N, Shinohara M, Bu G. APOE2: protective mechanism and therapeutic implications for Alzheimer\u2019s disease. Mol Neurodegener. 2020;15:63.","journal-title":"Mol Neurodegener"},{"key":"590_CR38","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a Meta-analysis. JAMA. 2015;313:1924\u201338.","journal-title":"JAMA"},{"key":"590_CR39","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/brain\/awy103","volume":"141","author":"S Mishra","year":"2018","unstructured":"Mishra S, Blazey TM, Holtzman DM, Cruchaga C, Su Y, Morris JC, et al. Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE \u03b54 genotype. Brain J Neurol. 2018;141:1828\u201339.","journal-title":"Brain J Neurol"},{"key":"590_CR40","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamaneurol.2020.3780","volume":"78","author":"PS Insel","year":"2021","unstructured":"Insel PS, Hansson O, Mattsson-Carlgren N. Association between apolipoprotein E \u03b52 vs \u03b54, age, and \u03b2-amyloid in adults without cognitive impairment. JAMA Neurol. 2021;78:229\u201335.","journal-title":"JAMA Neurol"},{"key":"590_CR41","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3233\/JAD-150252","volume":"49","author":"BE Gavett","year":"2016","unstructured":"Gavett BE, John SE, Gurnani AS, Bussell CA, Saurman JL. The role of Alzheimer\u2019s and cerebrovascular pathology in mediating the effects of age, race, and apolipoprotein E genotype on dementia severity in pathologically-confirmed Alzheimer\u2019s disease. J Alzheimers Dis JAD. 2016;49:531\u201345.","journal-title":"J Alzheimers Dis JAD"},{"key":"590_CR42","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/jnnp.2004.054445","volume":"76","author":"DA Bennett","year":"2005","unstructured":"Bennett DA, Schneider JA, Wilson RS, Bienias JL, Berry-Kravis E, Arnold SE. Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J Neurol Neurosurg Psychiatry. 2005;76:1194\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"590_CR43","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1093\/brain\/aws127","volume":"135","author":"RM Koffie","year":"2012","unstructured":"Koffie RM, Hashimoto T, Tai H-C, Kay KR, Serrano-Pozo A, Joyner D, et al. Apolipoprotein E4 effects in Alzheimer\u2019s disease are mediated by synaptotoxic oligomeric amyloid-\u03b2. Brain J Neurol. 2012;135:2155\u201368.","journal-title":"Brain J Neurol"},{"key":"590_CR44","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/ana.24369","volume":"77","author":"A Serrano-Pozo","year":"2015","unstructured":"Serrano-Pozo A, Qian J, Monsell SE, Betensky RA, Hyman BT. APOE\u03b52 is associated with milder clinical and pathological Alzheimer disease. Ann Neurol. 2015;77:917\u201329.","journal-title":"Ann Neurol"},{"key":"590_CR45","doi-asserted-by":"publisher","first-page":"E1807","DOI":"10.1073\/pnas.1220484110","volume":"110","author":"PB Verghese","year":"2013","unstructured":"Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, et al. ApoE influences amyloid-\u03b2 (A\u03b2) clearance despite minimal apoE\/A\u03b2 association in physiological conditions. Proc Natl Acad Sci U S A. 2013;110:E1807\u201316.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"590_CR46","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.1074\/jbc.M112.442103","volume":"288","author":"LM Tai","year":"2013","unstructured":"Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, et al. Levels of soluble apolipoprotein E\/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem. 2013;288:5914\u201326.","journal-title":"J Biol Chem"},{"key":"590_CR47","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1172\/JCI36663","volume":"118","author":"R Deane","year":"2008","unstructured":"Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002\u201313.","journal-title":"J Clin Invest"},{"key":"590_CR48","doi-asserted-by":"publisher","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","volume":"3","author":"JM Castellano","year":"2011","unstructured":"Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al. Human apoE isoforms differentially regulate brain amyloid-\u03b2 peptide clearance. Sci Transl Med. 2011;3:89ra57.","journal-title":"Sci Transl Med"},{"key":"590_CR49","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","volume":"58","author":"Q Jiang","year":"2008","unstructured":"Jiang Q, Lee CYD, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, et al. ApoE promotes the proteolytic degradation of A\u03b2. Neuron. 2008;58:681\u201393.","journal-title":"Neuron"},{"key":"590_CR50","doi-asserted-by":"publisher","first-page":"118553","DOI":"10.1016\/j.neuroimage.2021.118553","volume":"243","author":"CB Young","year":"2021","unstructured":"Young CB, Landau SM, Harrison TM, Poston KL, Mormino EC. Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [18F]-AV-1451 PET data. NeuroImage. 2021;243:118553.","journal-title":"NeuroImage"},{"key":"590_CR51","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523\u20137.","journal-title":"Nature"},{"key":"590_CR52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13024-019-0337-1","volume":"14","author":"T-PV Huynh","year":"2019","unstructured":"Huynh T-PV, Wang C, Tran AC, Tabor GT, Mahan TE, Francis CM, et al. Lack of hepatic apoE does not influence early A\u03b2 deposition: observations from a new APOE knock-in model. Mol Neurodegener. 2019;14:37.","journal-title":"Mol Neurodegener"},{"key":"590_CR53","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.neuron.2018.05.008","volume":"98","author":"Y-T Lin","year":"2018","unstructured":"Lin Y-T, Seo J, Gao F, Feldman HM, Wen H-L, Penney J, et al. APOE4 causes widespread molecular and cellular alterations associated with Alzheimer\u2019s disease phenotypes in human iPSC-derived brain cell types. Neuron. 2018;98:1141\u20131154.e7.","journal-title":"Neuron"},{"key":"590_CR54","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41591-018-0004-z","volume":"24","author":"C Wang","year":"2018","unstructured":"Wang C, Najm R, Xu Q, Jeong D-E, Walker D, Balestra ME, et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat Med. 2018;24:647\u201357.","journal-title":"Nat Med"},{"key":"590_CR55","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1038\/s41467-020-17805-1","volume":"11","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Song H, Zhang R, Pang K, Liu C, Song H, et al. Dynamic spatiotemporal beams that combine two independent and controllable orbital-angular-momenta using multiple optical-frequency-comb lines. Nat Commun. 2020;11:4099.","journal-title":"Nat Commun"},{"key":"590_CR56","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","volume":"23","author":"GB Frisoni","year":"2022","unstructured":"Frisoni GB, Altomare D, Thal DR, Ribaldi F, van der Kant R, Ossenkoppele R, et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci. 2022;23:53\u201366.","journal-title":"Nat Rev Neurosci"},{"key":"590_CR57","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/nm.3407","volume":"19","author":"B Obermeier","year":"2013","unstructured":"Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19:1584\u201396.","journal-title":"Nat Med"},{"key":"590_CR58","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","volume":"278","author":"LA Farrer","year":"1997","unstructured":"Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease Meta analysis consortium. JAMA. 1997;278:1349\u201356.","journal-title":"JAMA"},{"key":"590_CR59","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/jcbfm.2015.44","volume":"36","author":"MR Halliday","year":"2016","unstructured":"Halliday MR, Rege SV, Ma Q, Zhao Z, Miller CA, Winkler EA, et al. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer\u2019s disease. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2016;36:216\u201327.","journal-title":"J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab"},{"key":"590_CR60","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/jcbfm.2013.76","volume":"33","author":"K Hultman","year":"2013","unstructured":"Hultman K, Strickland S, Norris EH. The APOE \u025b4\/\u025b4 genotype potentiates vascular fibrin (ogen) deposition in amyloid-laden vessels in the brains of Alzheimer\u2019s disease patients. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2013;33:1251\u20138.","journal-title":"J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab"},{"key":"590_CR61","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.neuron.2014.12.056","volume":"85","author":"C Iadecola","year":"2015","unstructured":"Iadecola C. Dangerous leaks: blood-brain barrier woes in the aging Hippocampus. Neuron. 2015;85:231\u20133.","journal-title":"Neuron"},{"key":"590_CR62","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","volume":"581","author":"A Montagne","year":"2020","unstructured":"Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, et al. APOE4 leads to blood\u2013brain barrier dysfunction predicting cognitive decline. Nature. 2020;581:71\u20136.","journal-title":"Nature"},{"key":"590_CR63","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13195-022-00975-z","volume":"14","author":"R Panitch","year":"2022","unstructured":"Panitch R, Hu J, Xia W, Bennett DA, Stein TD, Farrer LA, et al. Blood and brain transcriptome analysis reveals APOE genotype-mediated and immune-related pathways involved in Alzheimer disease. Alzheimers Res Ther. 2022;14:30.","journal-title":"Alzheimers Res Ther"},{"key":"590_CR64","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.neurobiolaging.2019.09.020","volume":"85","author":"JM Riphagen","year":"2020","unstructured":"Riphagen JM, Ramakers IHGM, Freeze WM, Pagen LHG, Hanseeuw BJ, Verbeek MM, et al. Linking APOE-\u03b54, blood-brain barrier dysfunction, and inflammation to Alzheimer\u2019s pathology. Neurobiol Aging. 2020;85:96\u2013103.","journal-title":"Neurobiol Aging"},{"key":"590_CR65","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00401-022-02467-8","volume":"144","author":"D Sepulveda-Falla","year":"2022","unstructured":"Sepulveda-Falla D, Sanchez JS, Almeida MC, Boassa D, Acosta-Uribe J, Vila-Castelar C, et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer\u2019s dementia. Acta Neuropathol (Berl). 2022;144:589\u2013601.","journal-title":"Acta Neuropathol (Berl)"},{"key":"590_CR66","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13024-022-00556-6","volume":"17","author":"G Bu","year":"2022","unstructured":"Bu G. APOE targeting strategy in Alzheimer\u2019s disease: lessons learned from protective variants. Mol Neurodegener. 2022;17:51.","journal-title":"Mol Neurodegener"},{"key":"590_CR67","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1212\/WNL.0b013e3181a2e87d","volume":"72","author":"DA Bennett","year":"2009","unstructured":"Bennett DA, De Jager PL, Leurgans SE, Schneider JA. Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles. Neurology. 2009;72:1495\u2013503.","journal-title":"Neurology"},{"key":"590_CR68","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/aje\/155.6.487","volume":"155","author":"JE Eichner","year":"2002","unstructured":"Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. 2002;155:487\u201395.","journal-title":"Am J Epidemiol"},{"key":"590_CR69","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/aje\/kwu442","volume":"181","author":"S Kern","year":"2015","unstructured":"Kern S, Mehlig K, Kern J, Zetterberg H, Thelle D, Skoog I, et al. The distribution of apolipoprotein E genotype over the adult lifespan and in relation to country of birth. Am J Epidemiol. 2015;181:214\u20137.","journal-title":"Am J Epidemiol"},{"key":"590_CR70","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S1474-4422(18)30053-X","volume":"17","author":"SJ van der Lee","year":"2018","unstructured":"van der Lee SJ, Wolters FJ, Ikram MK, Hofman A, Ikram MA, Amin N, et al. The effect of APOE and other common genetic variants on the onset of Alzheimer\u2019s disease and dementia: a community-based cohort study. Lancet Neurol. 2018;17:434\u201344.","journal-title":"Lancet Neurol"},{"key":"590_CR71","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41583-019-0240-3","volume":"21","author":"R van der Kant","year":"2020","unstructured":"van der Kant R, Goldstein LSB, Ossenkoppele R. Amyloid-\u03b2-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci. 2020;21:21\u201335.","journal-title":"Nat Rev Neurosci"},{"key":"590_CR72","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/0140-6736(93)91728-5","volume":"342","author":"S Noguchi","year":"1993","unstructured":"Noguchi S, Murakami K, Yamada N, Payami H, Kaye J, Heston LL, et al. Apolipoprotein E genotype and Alzheimer\u2019s disease. Lancet. 1993;342:737\u20138.","journal-title":"Lancet"},{"key":"590_CR73","doi-asserted-by":"publisher","first-page":"e056269","DOI":"10.1002\/alz.056269","volume":"17","author":"TJ Betthauser","year":"2021","unstructured":"Betthauser TJ, Koscik RL, Jonaitis EM, Van Hulle CA, Basche KE, Kohli A, et al. Amyloid time: quantifying the onset of abnormal biomarkers and cognitive impairment along the Alzheimer\u2019s disease continuum. Alzheimers Dement. 2021;17:e056269.","journal-title":"Alzheimers Dement"},{"key":"590_CR74","first-page":"e12007","volume":"12","author":"RL Koscik","year":"2020","unstructured":"Koscik RL, Betthauser TJ, Jonaitis EM, Allison SL, Clark LR, Hermann BP, et al. Amyloid duration is associated with preclinical cognitive decline and tau PET. Alzheimers Dement Diagn Assess Dis Monit. 2020;12:e12007.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"590_CR75","doi-asserted-by":"publisher","first-page":"117676","DOI":"10.1016\/j.neuroimage.2020.117676","volume":"227","author":"PS Insel","year":"2021","unstructured":"Insel PS, Donohue MC, Berron D, Hansson O, Mattsson-Carlgren N. Time between milestone events in the Alzheimer\u2019s disease amyloid cascade. NeuroImage. 2021;227:117676.","journal-title":"NeuroImage"},{"key":"590_CR76","doi-asserted-by":"publisher","first-page":"e1823","DOI":"10.1212\/WNL.0000000000012775","volume":"97","author":"SE Schindler","year":"2021","unstructured":"Schindler SE, Li Y, Buckles VD, Gordon BA, Benzinger TLS, Wang G, et al. Predicting symptom onset in sporadic Alzheimer disease with amyloid PET. Neurology. 2021;97:e1823\u201334.","journal-title":"Neurology"},{"key":"590_CR77","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1016\/j.neurobiolaging.2015.08.008","volume":"36","author":"L Yu","year":"2015","unstructured":"Yu L, Boyle PA, Nag S, Leurgans S, Buchman AS, Wilson RS, et al. APOE and cerebral amyloid angiopathy in community-dwelling older persons. Neurobiol Aging. 2015;36:2946\u201353.","journal-title":"Neurobiol Aging"},{"key":"590_CR78","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/NEN.0b013e31829a25b9","volume":"72","author":"PT Nelson","year":"2013","unstructured":"Nelson PT, Pious NM, Jicha GA, Wilcock DM, Fardo DW, Estus S, et al. APOE-\u03b52 and APOE-\u03b54 correlate with increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp Neurol. 2013;72:708\u201315.","journal-title":"J Neuropathol Exp Neurol"},{"key":"590_CR79","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13024-017-0162-3","volume":"12","author":"L Saint-Aubert","year":"2017","unstructured":"Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-Vieitez E, Nordberg A. Tau PET imaging: present and future directions. Mol Neurodegener. 2017;12:19.","journal-title":"Mol Neurodegener"},{"key":"590_CR80","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.neurobiolaging.2021.09.019","volume":"109","author":"B Yoon","year":"2022","unstructured":"Yoon B, Guo T, Provost K, Korman D, Ward TJ, Landau SM, et al. Abnormal tau in amyloid PET negative individuals. Neurobiol Aging. 2022;109:125\u201334.","journal-title":"Neurobiol Aging"},{"key":"590_CR81","unstructured":"Lexeo Therapeutics, Alzheimer\u2019s Drug Discovery Foundation, Weill Medical College of Cornell University. Gene Therapy for APOE4 Homozygote of Alzheimer\u2019s Disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03634007."},{"key":"590_CR82","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s40263-016-0361-4","volume":"30","author":"Y Yamazaki","year":"2016","unstructured":"Yamazaki Y, Painter MM, Bu G, Kanekiyo T. Apolipoprotein E as a therapeutic target in Alzheimer\u2019s disease: a review of basic research and clinical evidence. CNS Drugs. 2016;30:773\u201389.","journal-title":"CNS Drugs"},{"key":"590_CR83","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s11095-019-2691-7","volume":"36","author":"RB dos Santos","year":"2019","unstructured":"dos Santos RB, Kanekiyo T, Singh J. ApoE-2 brain-targeted gene therapy through transferrin and Penetratin tagged liposomal nanoparticles. Pharm Res. 2019;36:161.","journal-title":"Pharm Res"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-022-00590-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-022-00590-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-022-00590-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T20:03:35Z","timestamp":1672776215000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-022-00590-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["590"],"URL":"https:\/\/doi.org\/10.1186\/s13024-022-00590-4","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"12 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All A4 participants completed written informed consent before participation. All ADNI participants provided written informed consent in compliance with local IRBs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KLP received consulting fees from CuraSen Therapeutics Inc. ECM is a paid consultant for Roche, Genentech, and Eli Lilly. All other authors have no disclosures relevant to the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}